Get Ready for Hep C Meds Mavyret and Vosevi
October 2017
You'll see home med lists that include new oral hepatitis C Rxs, Mavyret and Vosevi.
Mavyret (MAV-ih-reht, glecaprevir/pibrentasvir) will be another game changer. It's the first hep C med approved for just 8 weeks for initial therapy of all genotypes for most patients without cirrhosis.
It'll also be the lowest priced...about $26,400/course compared to $94,500 for Harvoni or $75,000 for Epclusa for 12 weeks.
Get concise advice on drug therapy, plus unlimited access to CE
Hospital Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote